lenalidomide has been researched along with Leishmaniasis, Visceral in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Camilleri, M; Checkley, A; Pomplun, S; Rabin, N; Richards, H; Wilson, A | 1 |
| Bacci, F; Di Bartolomeo, P; Morelli, AM; Pulini, S; Torti, L | 1 |
2 other study(ies) available for lenalidomide and Leishmaniasis, Visceral
| Article | Year |
|---|---|
Leishmaniasis as an unusual cause of pancytopenia in a patient receiving immunomodulatory therapy for myeloma.
Topics: Aged; Antiprotozoal Agents; Combined Modality Therapy; Drug Substitution; Endemic Diseases; Humans; Immunocompromised Host; Immunomodulation; Leishmania donovani; Leishmaniasis, Visceral; Lenalidomide; Male; Mediterranean Region; Multiple Myeloma; Pancytopenia; Phosphorylcholine; Recurrence; Renal Dialysis; Travel-Related Illness | 2020 |
Visceral leishmaniasis in relapsed and overtreated multiple myeloma in the era of high dose and "novel agent" therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Cyclophosphamide; Dexamethasone; Humans; Leishmaniasis, Visceral; Lenalidomide; Male; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Thalidomide | 2015 |